Twist Bioscience logo

Twist BioscienceNASDAQ: TWST

Profile

Sector:

Healthcare

Country:

United States

IPO:

31 October 2018

Next earnings report:

31 January 2025

Last dividends:

N/A

Next dividends:

N/A
$2.50 B
-54%vs. 3y high
83%vs. sector
-vs. 3y high
-vs. sector
-44%vs. 3y high
83%vs. sector
-80%vs. 3y high
73%vs. sector

Price

pre-market | 3 min ago
$42.04+$0.87(+2.11%)

Dividend

No data over the past 3 years
$84.71 M$86.92 M
$84.71 M-$34.66 M

Analysts recommendations

Institutional Ownership

TWST Latest News

Twist Bioscience: A Post-Earnings Assessment
seekingalpha.com18 November 2024 Sentiment: POSITIVE

Twist Biosciences just posted a solid Q4, which had the stock rising in trading Monday. However, despite impressive sales growth, Twist Biosciences remains unprofitable, with projected losses for several years even as revenues rise. The company does have a solid balance sheet and north of $1.2 billion in net loss carry forwards.

Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates
zacks.com18 November 2024 Sentiment: POSITIVE

Twist Bioscience (TWST) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $0.81 per share a year ago.

Twist Bioscience's Earnings Preview: Partnerships And Valuation Make It A 'Buy'
seekingalpha.com08 November 2024 Sentiment: POSITIVE

Since I last covered it, Twist Bioscience has made significant strides. They have secured new partnerships, launched innovative products, and secured strategic financial agreements. TWST's valuation multiples now appear more reasonable, making it a compelling buy for new investors, with a long cash runway and potential self-sustainability by 2025-2026. The company has improved its gross margins and reduced EBIT margins, signaling rapid margin improvement and benefiting from economies of scale.

Twist Bioscience Launches FlexPrep™ Ultra-High Throughput Library Preparation Kit for Applications in Agrigenomics and Population Genomics
businesswire.com30 October 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of the FlexPrep™ Ultra-High Throughput Library Preparation Kit, designed with a proprietary Twist-developed enzyme to enable throughput at a low cost, and accelerate the adoption of NGS by microarray users in population and agricultural genomics (agrigenomics).

Twist Bioscience: Lowered Biopharma Expectations Amid Financial Strain (Rating Downgrade)
seekingalpha.com04 August 2024 Sentiment: NEUTRAL

Twist Bioscience reported revenue of $81.5 million in Q2 (fiscal Q3), marking a 28% increase from Q2, 2023. Twist's biopharma segment underperformed, contributing to a significant impairment charge. The company's future relies on its synthetic biology segment, facing competition and uncertain prospects in a rapidly evolving market.

Twist Bioscience Corporation (TWST) Q3 2024 Earnings Call Transcript
seekingalpha.com02 August 2024 Sentiment: POSITIVE

Twist Bioscience Corporation (NASDAQ:TWST ) Q3 2024 Earnings Conference Call August 2, 2024 8:00 AM ET Company Participants Angela Bitting - Senior Vice President, Corporate Affairs Emily Leproust - Chief Executive Officer & Co-Founder Adam Laponis - Chief Financial Officer Patrick Finn - President and COO Conference Call Participants Steven Mah - Cowen Matt Larew - William Blair Luke Sergott - Barclays Vijay Kumar - Evercore ISI Sung-Ji Nam - Scotiabank Subbu Nambi - Guggenheim Securities Puneet Souda - Leerink Partners Tom Peterson - Baird Thomas DeBourcy - Nephron Research Operator Good day, and thank you for standing by. Welcome to Twist Bioscience Fiscal 2024 Third Quarter Financial Results Conference Call.

Twist Bioscience Reports Fiscal Third Quarter 2024 Financial Results
businesswire.com02 August 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the third quarter of fiscal 2024 ended June 30, 2024. "We once again surpassed our revenue guidance, ending the quarter with $81.5 million in revenue, and exceeded our targets for both cash burn and gross margin," said Emily M.

Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
zacks.com22 July 2024 Sentiment: POSITIVE

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Twist Bioscience to Report Fiscal 2024 Third Quarter Financial Results on Friday, August 2, 2024
businesswire.com11 July 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 third quarter ended June 30, 2024, before the opening of the market on Friday, August 2, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Ti.

Twist Bioscience Publishes Preclinical Data Detailing Discovery of Antibody Targeting Emerging Checkpoint Inhibitor
businesswire.com06 June 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the publication of a study detailing the discovery of TB206-001, a first-in-class antibody targeting adenosine A2A receptor (A2AR), a promising molecular target that could enhance cancer immunotherapy. The study titled, “Discovery of a potent, selective, and tumor-suppress.

  • 1(current)

What type of business is Twist Bioscience?

Twist Bioscience Corp is a company specializing in synthetic biology. It is developing a breakthrough DNA synthesis platform for the industrialization of biological engineering. The company's DNA synthesis platform uses a patented process for producing synthetic DNA based on semiconductors, which synthesizes DNA on silicon rather than on traditional plastic plates with wells, allowing for faster and more affordable production of high-quality synthetic DNA, eliminating inefficiencies and ensuring cost-effectiveness, rapid high-throughput synthesis, enabling researchers to quickly realize opportunities. Geographically, it derives most of its revenue from the United States. The company was founded in 2013 and is headquartered in South San Francisco, California.

What sector is Twist Bioscience in?

Twist Bioscience is in the Healthcare sector

What industry is Twist Bioscience in?

Twist Bioscience is in the Diagnostics & Research industry

What country is Twist Bioscience from?

Twist Bioscience is headquartered in United States

When did Twist Bioscience go public?

Twist Bioscience initial public offering (IPO) was on 31 October 2018

What is Twist Bioscience website?

https://www.twistbioscience.com

Is Twist Bioscience in the S&P 500?

No, Twist Bioscience is not included in the S&P 500 index

Is Twist Bioscience in the NASDAQ 100?

No, Twist Bioscience is not included in the NASDAQ 100 index

Is Twist Bioscience in the Dow Jones?

No, Twist Bioscience is not included in the Dow Jones index

When was Twist Bioscience the previous earnings report?

No data

When does Twist Bioscience earnings report?

The next expected earnings date for Twist Bioscience is 31 January 2025